A study of mothers and their young babies by neurologists at UCSF has shown that mothers who suffer migraine headaches are more than twice as likely to have babies with colic than mothers without a history of migraines.
February 20, 2012
February 15, 2012
A major clinical trial conducted with patients experiencing a prolonged convulsive seizure has shown that injecting drugs into the thigh muscle is just as safe and more effective than giving the medication intravenously.
January 30, 2012
Richard K. Olney, MD, founding director of the ALS Treatment and Research Center at UCSF and a pioneer in clinical research on amyotrophic lateral sclerosis (ALS), has died at age 64, following his own eight-year battle with the disease.
January 25, 2012
Scientists at the UCSF-affiliated Gladstone Institutes have identified a protein that exacerbates symptoms of Parkinson’s disease — a discovery that could one day lead to new treatments for people who suffer from this devastating neurodegenerative illness.
January 23, 2012
A UCSF team has developed methods to reveal a molecular marker in tissue samples from brain tumors that has been linked to better survival odds.
January 23, 2012
More than 4,000 people with various forms of epilepsy will have their DNA decoded over the next five years in a study led by researchers at UCSF and several collaborating institutions.
January 18, 2012
Dogs with spinal cord injuries may soon benefit from an experimental drug being tested by researchers at UCSF and Texas A&M College of Veterinary Medicine & Biomedical Sciences — work that they hope will one day help people with similar injuries.
December 16, 2011
A large, international team of researchers led by scientists at UCSF has identified the gene that causes a rare childhood neurological disorder called PKD/IC, or “paroxysmal kinesigenic dyskinesia with infantile convulsions,” a cause of epilepsy in babies and movement disorders in older children.
November 14, 2011
November 01, 2011
An experimental drug called Ocrelizumab has shown promise in a Phase 2 clinical trial involving 220 people with multiple sclerosis (MS), an often debilitating, chronic autoimmune disease that affects an increasing number of people in North America.